![](/img/cover-not-exists.png)
76PTislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study
Sandhu, S, Hill, A, Gan, H, Friedlander, M, Voskoboynik, M, Barlow, P, Townsend, A, Song, J, Zhang, Y, Liang, L, Desai, JVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy487.007
Date:
December, 2018
File:
PDF, 77 KB
2018